Trading a BMEA straddle lets you take a pure volatility position on Biomea Fusion Inc without committing to a direction. Biomea Fusion Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate BMEA straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on BMEA profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Biomea Fusion Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the BMEA straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the BMEA straddle is the cleanest expression of that view. Our scanner prices every BMEA straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a BMEA straddle into a catalyst or short a BMEA straddle to harvest decay, the options straddle setups that matter are all in one place.
